Avodart Study Points to Possible Heart Failure RiskApr 1, 2010 | Parker Waichman LLP
Men who take Avodart to prevent prostate cancer may be at higher risk of heart failure, according to a new study.
According to the Associated Press, the study that raised the heart risk association was designed to test Avodart as a prostate cancer preventive. It involved 6,700 men with high scores from PSA blood tests but no sign of cancer on biopsy who were treated either with Avodart or a placebo. Heart failure developed in 30 men on Avodart, compared to only 16 treated with placebo..
Prostate cancer was found in 25 percent of those placebo, compared with 20 percent of those on Avodart.
Avodart was approved in 2002 to treat urinary problems, including enlarged prostate. On Monday, GlaxoSmithKline, the maker of Avodart, asked the Food & Drug Administration (FDA) to approve the drug as a preventive treatment for men at high risk for prostate cancer.
According to the Associated Press, the same reduction in prostate cancer has been seen with another drug, Proscar, sold generically as finasteride. However, a higher risk of heart failure has not been connected to Proscar.